Information about Trifluoperazine
Trifluoperazine is a phenothiazine and antipsychotic agent that no longer commonly used in clinical practice.
Liver safety of Trifluoperazine
Trifluoperazine is a rare cause of clinically apparent acute cholestatic liver injury.
Mechanism of action of Trifluoperazine
Trifluoperazine (trye" floo oh per' a zeen) is a piperazine phenothiazine derivative which acts by postsynaptic inhibition of dopamine receptors. Trifluoperazine has other peripheral and central nervous system effects, producing both alpha adrenergic stimulation and blocking histamine- and serotonin-mediated effects. Trifluoperazine is indicated for the therapy of acute and chronic psychosis and rarely for nonpsychotic anxiety.
FDA approval information for Trifluoperazine
Trifluoperazine was approved for use in the United States in 1959 and was formerly a commonly prescribed antipsychotic medication, but has been replaced in recent years in large part by the atypical antipsychotics, which have fewer extrapyramidal side effects.
Dosage and administration for Trifluoperazine
Trifluoperazine is available as tablets of 1, 2, 5 and 10 mg in generic forms and formerly under the brand name of Stelazine. Oral solutions and parenteral formulations are also available. The typical recommended dose in adults in 1 to 2 mg twice daily, increasing as needed to a maximum of 6 mg daily.
Side effects of Trifluoperazine
Second Generation (Atypicals)
- Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Pimavanserin, Quetiapine, Risperidone, Ziprasidone